New scan may predict which breast cancer patients benefit from targeted drug

NCT ID NCT07471776

Recruiting now Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Mar 17, 2026 · Last updated Apr 29, 2026 · Updated 9 times

Summary

This study tests whether a new type of PET scan (TROP2-PET) can predict if a targeted drug will work for people with advanced HER2-negative breast cancer. About 45 participants will get both a standard and a TROP2-PET scan before starting treatment. The goal is to see if the scan can help doctors choose the right therapy for each patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC BREAST CANCER ( HER2 NEGATIVE)